Concepts (185)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Thyroid Neoplasms | 9 | 2019 | 34 | 3.510 |
Why?
|
| Thyroidectomy | 8 | 2020 | 20 | 2.670 |
Why?
|
| Hyperthermia, Induced | 11 | 2015 | 236 | 2.180 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2019 | 372 | 2.010 |
Why?
|
| Peritoneal Neoplasms | 9 | 2014 | 256 | 1.720 |
Why?
|
| Hyperparathyroidism, Primary | 4 | 2018 | 16 | 1.640 |
Why?
|
| Parathyroidectomy | 5 | 2020 | 20 | 1.540 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 10 | 2014 | 154 | 1.360 |
Why?
|
| Adenocarcinoma, Follicular | 2 | 2019 | 2 | 1.120 |
Why?
|
| Retrospective Studies | 22 | 2020 | 3612 | 1.100 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2014 | 442 | 1.040 |
Why?
|
| Middle Aged | 30 | 2020 | 11848 | 1.010 |
Why?
|
| Lymph Node Excision | 2 | 2017 | 94 | 0.980 |
Why?
|
| Carcinoma, Papillary | 4 | 2017 | 14 | 0.900 |
Why?
|
| Carcinoma, Neuroendocrine | 2 | 2016 | 14 | 0.890 |
Why?
|
| Female | 32 | 2020 | 19955 | 0.860 |
Why?
|
| Male | 29 | 2020 | 19448 | 0.800 |
Why?
|
| Postoperative Complications | 4 | 2017 | 818 | 0.800 |
Why?
|
| Humans | 35 | 2020 | 32286 | 0.750 |
Why?
|
| Adenocarcinoma | 2 | 2016 | 298 | 0.740 |
Why?
|
| Follow-Up Studies | 13 | 2019 | 2238 | 0.740 |
Why?
|
| Thyroid Gland | 2 | 2019 | 16 | 0.740 |
Why?
|
| Appendiceal Neoplasms | 4 | 2015 | 99 | 0.680 |
Why?
|
| Adult | 17 | 2020 | 9263 | 0.670 |
Why?
|
| Aged | 18 | 2020 | 10259 | 0.670 |
Why?
|
| Hyperparathyroidism | 1 | 2020 | 9 | 0.650 |
Why?
|
| Neoplasm Staging | 10 | 2019 | 458 | 0.650 |
Why?
|
| Neoplasms | 4 | 2014 | 762 | 0.620 |
Why?
|
| Combined Modality Therapy | 10 | 2019 | 550 | 0.610 |
Why?
|
| Survival Rate | 10 | 2019 | 892 | 0.600 |
Why?
|
| Faculty, Medical | 1 | 2020 | 76 | 0.600 |
Why?
|
| Thyroid Nodule | 1 | 2019 | 6 | 0.600 |
Why?
|
| Hashimoto Disease | 1 | 2019 | 1 | 0.590 |
Why?
|
| Surgical Procedures, Operative | 1 | 2020 | 79 | 0.590 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2019 | 2 | 0.590 |
Why?
|
| Autoantibodies | 1 | 2019 | 50 | 0.580 |
Why?
|
| Quality of Health Care | 1 | 2019 | 148 | 0.550 |
Why?
|
| Carcinoma, Medullary | 1 | 2017 | 1 | 0.540 |
Why?
|
| Potassium Iodide | 1 | 2017 | 1 | 0.540 |
Why?
|
| Graves Disease | 1 | 2017 | 5 | 0.530 |
Why?
|
| Clinical Competence | 1 | 2020 | 329 | 0.520 |
Why?
|
| Hypercalcemia | 1 | 2017 | 12 | 0.520 |
Why?
|
| Prognosis | 9 | 2017 | 1529 | 0.520 |
Why?
|
| Treatment Outcome | 9 | 2020 | 3409 | 0.520 |
Why?
|
| Fear | 1 | 2017 | 42 | 0.510 |
Why?
|
| Emotions | 1 | 2017 | 55 | 0.500 |
Why?
|
| Primary Health Care | 1 | 2019 | 232 | 0.500 |
Why?
|
| Phenoxybenzamine | 1 | 2016 | 2 | 0.490 |
Why?
|
| Doxazosin | 1 | 2016 | 5 | 0.490 |
Why?
|
| Pheochromocytoma | 1 | 2016 | 6 | 0.490 |
Why?
|
| Adrenalectomy | 1 | 2016 | 33 | 0.490 |
Why?
|
| Internship and Residency | 1 | 2020 | 317 | 0.480 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2016 | 17 | 0.480 |
Why?
|
| Hypocalcemia | 1 | 2016 | 13 | 0.480 |
Why?
|
| Choledochal Cyst | 1 | 2015 | 6 | 0.450 |
Why?
|
| Preoperative Care | 1 | 2016 | 126 | 0.450 |
Why?
|
| Vitamin D Deficiency | 1 | 2016 | 87 | 0.450 |
Why?
|
| Registries | 1 | 2016 | 294 | 0.440 |
Why?
|
| Abdominal Cavity | 1 | 2014 | 6 | 0.420 |
Why?
|
| Laparoscopy | 1 | 2016 | 184 | 0.420 |
Why?
|
| Stomach Neoplasms | 1 | 2016 | 113 | 0.420 |
Why?
|
| Abdominal Neoplasms | 1 | 2014 | 13 | 0.420 |
Why?
|
| Carcinoma | 1 | 2015 | 92 | 0.420 |
Why?
|
| Gallbladder Neoplasms | 1 | 2014 | 35 | 0.420 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2013 | 6 | 0.400 |
Why?
|
| Ampulla of Vater | 1 | 2013 | 6 | 0.400 |
Why?
|
| Duodenal Neoplasms | 1 | 2013 | 7 | 0.400 |
Why?
|
| Carcinoid Tumor | 1 | 2013 | 13 | 0.400 |
Why?
|
| Vesiculovirus | 1 | 2013 | 4 | 0.400 |
Why?
|
| Oncolytic Viruses | 1 | 2013 | 8 | 0.400 |
Why?
|
| Ascites | 1 | 2013 | 13 | 0.400 |
Why?
|
| Oncolytic Virotherapy | 1 | 2013 | 16 | 0.390 |
Why?
|
| Neuroendocrine Tumors | 1 | 2013 | 19 | 0.390 |
Why?
|
| Antineoplastic Agents | 2 | 2015 | 595 | 0.390 |
Why?
|
| Liver Neoplasms | 1 | 2014 | 164 | 0.380 |
Why?
|
| Sarcoma | 1 | 2013 | 82 | 0.370 |
Why?
|
| Case-Control Studies | 4 | 2016 | 854 | 0.350 |
Why?
|
| Diabetes Mellitus | 1 | 2014 | 390 | 0.340 |
Why?
|
| Young Adult | 7 | 2017 | 2652 | 0.340 |
Why?
|
| Prospective Studies | 8 | 2017 | 2317 | 0.320 |
Why?
|
| Survival Analysis | 3 | 2016 | 476 | 0.320 |
Why?
|
| United States | 4 | 2020 | 4077 | 0.300 |
Why?
|
| Risk Assessment | 3 | 2019 | 1424 | 0.270 |
Why?
|
| SEER Program | 2 | 2016 | 38 | 0.220 |
Why?
|
| Aged, 80 and over | 5 | 2016 | 3899 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 2 | 2016 | 180 | 0.220 |
Why?
|
| Databases, Factual | 2 | 2016 | 367 | 0.210 |
Why?
|
| North Carolina | 3 | 2016 | 1300 | 0.210 |
Why?
|
| Postural Balance | 1 | 2016 | 142 | 0.210 |
Why?
|
| Pesticides | 1 | 2016 | 135 | 0.210 |
Why?
|
| Diaphragm | 2 | 2014 | 37 | 0.210 |
Why?
|
| Occupational Exposure | 1 | 2016 | 159 | 0.210 |
Why?
|
| Transients and Migrants | 1 | 2016 | 197 | 0.200 |
Why?
|
| Emigrants and Immigrants | 1 | 2016 | 198 | 0.200 |
Why?
|
| Colonic Neoplasms | 2 | 2014 | 70 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 4 | 2014 | 185 | 0.170 |
Why?
|
| Child | 4 | 2017 | 2432 | 0.170 |
Why?
|
| Hispanic Americans | 1 | 2016 | 772 | 0.170 |
Why?
|
| Mentors | 1 | 2020 | 33 | 0.160 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 18 | 0.160 |
Why?
|
| Trust | 1 | 2020 | 43 | 0.150 |
Why?
|
| Ultrasonography | 2 | 2019 | 394 | 0.150 |
Why?
|
| Adolescent | 4 | 2017 | 3519 | 0.150 |
Why?
|
| Quality of Life | 2 | 2017 | 970 | 0.150 |
Why?
|
| Thyrotropin | 1 | 2019 | 7 | 0.150 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 161 | 0.150 |
Why?
|
| Guideline Adherence | 1 | 2019 | 109 | 0.140 |
Why?
|
| Referral and Consultation | 1 | 2019 | 138 | 0.140 |
Why?
|
| Societies, Medical | 1 | 2019 | 153 | 0.140 |
Why?
|
| Pain, Postoperative | 1 | 2020 | 198 | 0.130 |
Why?
|
| Feasibility Studies | 2 | 2020 | 309 | 0.130 |
Why?
|
| Wisconsin | 1 | 2017 | 21 | 0.130 |
Why?
|
| Diagnosis, Differential | 1 | 2019 | 501 | 0.130 |
Why?
|
| Parathyroid Glands | 1 | 2017 | 7 | 0.130 |
Why?
|
| Parathyroid Neoplasms | 1 | 2017 | 7 | 0.130 |
Why?
|
| Lymphatic Metastasis | 2 | 2014 | 168 | 0.130 |
Why?
|
| Mitomycin | 2 | 2014 | 50 | 0.130 |
Why?
|
| Cisplatin | 2 | 2014 | 77 | 0.130 |
Why?
|
| Interviews as Topic | 1 | 2017 | 195 | 0.120 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 128 | 0.120 |
Why?
|
| Research Design | 1 | 2018 | 316 | 0.120 |
Why?
|
| Choristoma | 1 | 2016 | 14 | 0.120 |
Why?
|
| Teratoma | 1 | 2016 | 9 | 0.120 |
Why?
|
| Practice Guidelines as Topic | 1 | 2019 | 395 | 0.120 |
Why?
|
| Preoperative Period | 1 | 2016 | 30 | 0.120 |
Why?
|
| Qualitative Research | 1 | 2017 | 180 | 0.120 |
Why?
|
| Disease-Free Survival | 1 | 2016 | 322 | 0.120 |
Why?
|
| Abdomen | 1 | 2016 | 44 | 0.120 |
Why?
|
| Vitamins | 1 | 2016 | 70 | 0.110 |
Why?
|
| Gastrectomy | 1 | 2016 | 70 | 0.110 |
Why?
|
| Hemodynamics | 1 | 2016 | 164 | 0.110 |
Why?
|
| Cholangiopancreatography, Magnetic Resonance | 1 | 2015 | 8 | 0.110 |
Why?
|
| Common Bile Duct | 1 | 2015 | 6 | 0.110 |
Why?
|
| Dilatation, Pathologic | 1 | 2015 | 20 | 0.110 |
Why?
|
| Ovarian Neoplasms | 1 | 2016 | 84 | 0.110 |
Why?
|
| Neoplasm Metastasis | 1 | 2016 | 221 | 0.110 |
Why?
|
| Intraoperative Care | 1 | 2015 | 52 | 0.110 |
Why?
|
| Vitamin D | 1 | 2016 | 186 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 650 | 0.110 |
Why?
|
| Pneumonia | 1 | 2014 | 62 | 0.110 |
Why?
|
| Pancreatectomy | 1 | 2014 | 25 | 0.100 |
Why?
|
| Omentum | 1 | 2014 | 25 | 0.100 |
Why?
|
| Thrombosis | 1 | 2014 | 78 | 0.100 |
Why?
|
| Colectomy | 1 | 2014 | 30 | 0.100 |
Why?
|
| Respiratory Insufficiency | 1 | 2014 | 60 | 0.100 |
Why?
|
| Hepatectomy | 1 | 2014 | 57 | 0.100 |
Why?
|
| Intensive Care Units | 1 | 2014 | 121 | 0.100 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 100 | 0.100 |
Why?
|
| Viral Matrix Proteins | 1 | 2013 | 12 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2014 | 202 | 0.100 |
Why?
|
| Tumor Burden | 1 | 2013 | 62 | 0.100 |
Why?
|
| Interferon-beta | 1 | 2013 | 19 | 0.100 |
Why?
|
| Hospital Mortality | 1 | 2014 | 197 | 0.100 |
Why?
|
| Length of Stay | 1 | 2014 | 321 | 0.100 |
Why?
|
| Urinary Tract | 1 | 2013 | 31 | 0.100 |
Why?
|
| Urologic Diseases | 1 | 2013 | 35 | 0.100 |
Why?
|
| Incidence | 1 | 2016 | 1243 | 0.100 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 114 | 0.100 |
Why?
|
| Peritoneum | 1 | 2013 | 32 | 0.100 |
Why?
|
| Mice, Nude | 1 | 2013 | 285 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2013 | 773 | 0.090 |
Why?
|
| Cell Line, Tumor | 1 | 2013 | 727 | 0.090 |
Why?
|
| Mutation | 1 | 2013 | 497 | 0.080 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2015 | 905 | 0.080 |
Why?
|
| Risk Factors | 1 | 2016 | 3937 | 0.070 |
Why?
|
| Mice | 1 | 2013 | 2571 | 0.070 |
Why?
|
| Obesity | 1 | 2013 | 1111 | 0.060 |
Why?
|
| Animals | 1 | 2013 | 8197 | 0.040 |
Why?
|
| Hydrocodone | 1 | 2020 | 1 | 0.040 |
Why?
|
| Drug Utilization | 1 | 2020 | 44 | 0.040 |
Why?
|
| Acetaminophen | 1 | 2020 | 19 | 0.040 |
Why?
|
| Drug Combinations | 1 | 2020 | 102 | 0.040 |
Why?
|
| Drug Prescriptions | 1 | 2020 | 54 | 0.040 |
Why?
|
| Pain Measurement | 1 | 2020 | 340 | 0.040 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 230 | 0.030 |
Why?
|
| Thyroglobulin | 1 | 2017 | 2 | 0.030 |
Why?
|
| Analgesics, Opioid | 1 | 2020 | 251 | 0.030 |
Why?
|
| Reoperation | 1 | 2017 | 247 | 0.030 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2014 | 10 | 0.030 |
Why?
|
| Injections, Intraperitoneal | 1 | 2014 | 45 | 0.030 |
Why?
|
| Morbidity | 1 | 2014 | 98 | 0.030 |
Why?
|
| Perfusion | 1 | 2014 | 75 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2017 | 1234 | 0.020 |
Why?
|
| Organoplatinum Compounds | 1 | 2013 | 41 | 0.020 |
Why?
|
| Carboplatin | 1 | 2013 | 42 | 0.020 |
Why?
|